<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 AM</td>
<td><strong>Registration and Breakfast</strong>  HUB Ballroom (Husky Union Building)</td>
</tr>
<tr>
<td>8:15 AM</td>
<td><strong>Welcome</strong>  Kane Hall</td>
</tr>
</tbody>
</table>
| 8:30 AM  | **KEYNOTE PRESENTATION**  
**UKCTOCs – exploring the results**  
Usha Menon, MD FRCOG • University College London (United Kingdom) |
| 9:15 AM  | **INVITED SPEAKER PRESENTATION**  
**Impacting ovarian cancer mortality through innovative prevention strategies**  
Karen Lu, MD • University of Texas MD Anderson Cancer Center |
| 9:45 AM  | **ABSTRACT SESSION**  
**Methylation profiling of ovarian cancer to study etiologic and prognostic heterogeneity and to develop a molecular classifier**  
Clara Bodelon, PhD • National Cancer Institute |
| 10:00 AM | **HE4 is a biomarker for newly diagnosed and recurrent high-grade serous ovarian cancers with normal CA-125 values**  
Katherine LaVigne, MD • Memorial Sloan Kettering Cancer Center |
| 10:15 AM | **BREAK**                                                   |
| 10:35 AM | **ABSTRACT SESSION CONTINUED**  
**Ovarian cancer early detection program (OCEDP)**  
Saul E. Rivkin, MD • Rivkin Center for Ovarian Cancer and Swedish Medical Center |
| 10:50 AM | **Ovarian cancer and pulp and paper manufacturing in the US: A geospatial analysis**  
Carol Hanchette, PhD • University of Louisville |
| 11:05 AM | **The molecular detection of circulating tumor cells in the blood of ovarian cancer patients**  
Eva Obermayr, PhD • Medical University of Vienna |
| 11:20 AM | **Ultra-deep sequencing detects ovarian cancer cells in peritoneal fluid and reveals somatic TP53 mutations in non-cancerous tissues**  
Rosana Risques, PhD • University of Washington |
| 11:35 AM | **Subclinical significance of circulating tumor cells in epithelial ovarian cancer as an early indicator of recurrence**  
Carmen Ruiz, PhD • University of Southern California |
| 11:50 AM | **Use of common medications and survival after ovarian cancer diagnosis**  
Elizabeth Poole, PhD • Brigham and Women’s Hospital |
| 12:05 PM – 1:30 PM | **Lunch Break**  HUB Ballroom (Husky Union Building) |
| 12:30 PM – 1:30 PM | **Meet the Experts Roundtable Discussions**  HUB Ballroom (Husky Union Building) |

Except where otherwise noted, all oral presentation sessions will be in Kane Hall.
Staring down the barrel of a tube at the origins of ovarian cancer
Ronny Drapkin, MD • University of Pennsylvania

BCAM-AKT2 fusion gene leads to a constitutively activated AKT2 fusion kinase in HGSC
Laising Yen, PhD • Baylor College of Medicine

Genomics of ovarian cancer progression reveals diverse metastatic trajectories including intraepithelial metastasis to the fallopian tube
Ernst Lengyel, MD, PhD • University of Chicago

Genomic Alterations in Endometriosis
Michael Anglesio, PhD • University of British Columbia (Canada)

A Novel Pan-ALDH1A Inhibitor Induces Necroptosis in Ovarian Cancer Stem-Like cells and Synergizes with Chemotherapy to Improve Outcomes
Ronald Buckanovich, MD, PhD • University of Michigan

PAX2 function, regulation, and targeting in Fallopian tube-derived high grade serous ovarian cancer
Joanna Burdette, PhD • University of Illinois at Chicago

Cysteine Metabolism in Clear Cell Ovarian Cancer
Dawn Cochrane, PhD • BC Cancer Agency (Canada)

NF-κappaB classical versus alternative pathways support distinct populations of ovarian cancer tumor-initiating cells
Carrie House, PhD • National Cancer Institute

Therapeutic targeting using tumor specific peptides inhibits long non-coding RNA HOTAIR oncogenic activity in ovarian cancer
Kenneth Nephew, PhD • Indiana University School of Medicine

Modulation of oxidative stress and subsequent induction of apoptosis and endoplasmic reticulum stress allows citral to decrease cancer cell proliferation
Manish Patankar, PhD • University of Wisconsin-Madison

The Critical Role of p53-Twist1 Axis in Ovarian Cancer Metastasis
Yang Yang-Hartwich, PhD • Yale School of Medicine

WRAP UP

POSTER SESSION & RECEPTION HUB Ballroom (Husky Union Building)

Please see the walking route on the back cover.
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30 AM</td>
<td><strong>Registration and Breakfast</strong> HUB Ballroom (Husky Union Building)</td>
</tr>
<tr>
<td>8:30 AM</td>
<td><strong>KEYNOTE PRESENTATION</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Overcoming Adaptive Changes in the Tumor Microenvironment</strong> Anil Sood, MD • University of Texas MD Anderson Cancer Center</td>
</tr>
<tr>
<td>9:15 AM</td>
<td><strong>INVITED SPEAKER PRESENTATION</strong></td>
</tr>
<tr>
<td></td>
<td><strong>The Origins and Early Development of Ovarian Cancer: Cells, Mutation and Environment</strong> David Huntsman, MD • University of British Columbia &amp; British Columbia Cancer Agency (Canada)</td>
</tr>
<tr>
<td>9:45 AM</td>
<td><strong>ABSTRACT SESSION</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Ovarian Tumor Stimulation Converts Normal Ovary and Omental Mesenchymal Stem Cells into Tumor-Promoting Carcinoma-Associated Mesenchymal Stem Cells</strong> Lan Coffman, MD, PhD • University of Michigan</td>
</tr>
<tr>
<td>10:00 AM</td>
<td><strong>FUNCTIONAL GENOMIC SCREEN FOR ATTACHMENT AND INVASION IN METASTATIC OVARIAN CANCER</strong> Katherine Fuh, MD, PhD • Washington University School of Medicine</td>
</tr>
<tr>
<td>10:15 AM</td>
<td><strong>BREAK</strong></td>
</tr>
<tr>
<td>10:35 AM</td>
<td><strong>ABSTRACT SESSION CONTINUED</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Single-cell RNA-sequencing of patient-derived ovarian cancer cells and patient-derived xenograft models</strong> Benjamin Izar, MD, PhD • Dana-Farber Cancer Institute and Broad Institute of MIT and Harvard</td>
</tr>
<tr>
<td>10:50 AM</td>
<td><strong>A pilot study of a poly (ADP-ribose) polymerase-1 (PARP) targeted novel PET tracer (18F-Fluourthranotrace) in patients with ovarian carcinoma</strong> Lilie Lin, MD • University of Pennsylvania</td>
</tr>
<tr>
<td>11:05 AM</td>
<td><strong>LIPID DESATURATION IS A METABOLIC MARKER AND THERAPEUTIC TARGET OF OVARIAN CANCER STEM CELLS</strong> Daniela Matei, MD • Northwestern University Feinberg School of Medicine</td>
</tr>
<tr>
<td>11:20 AM</td>
<td><strong>CHEMoresistance, Tumor Initiation and Tumor Re-emergence Trends in Malignant Ascites-Derived Ovarian Cancer Stem Cell Spheroids</strong> Shreya Raghavan, PhD • University of Michigan</td>
</tr>
<tr>
<td>11:35 AM</td>
<td><strong>A platinum-resistant subtype of high-grade serous ovarian cancer identified by a network of somatic mutations</strong> John Paul Shen, MD • University of California, San Diego</td>
</tr>
<tr>
<td>11:50 AM</td>
<td><strong>CRISPR/Cas9-mediated Trp53, Brca1, Brca2 and Pten knockout to generate improved murine models of ovarian high grade serous carcinoma</strong> Josephine Walton, PhD • University of Glasgow (United Kingdom)</td>
</tr>
<tr>
<td>12:05 PM</td>
<td><strong>Lunch Break</strong> HUB Ballroom (Husky Union Building)</td>
</tr>
<tr>
<td>12:30 PM</td>
<td><strong>MEET THE EXPERTS ROUNDTABLE DISCUSSIONS</strong> HUB Ballroom (Husky Union Building)</td>
</tr>
</tbody>
</table>
### ABSTRACT SESSION

**Inhibition of HDAC activity selectively inhibits ARID1A-mutated ovarian clear cell carcinoma through a novel p53 regulatory mechanism**  
Benjamin Bitler, PhD • The Wistar Institute

**SMAC-mimetic treatment enhances antitumor effect of standard chemotherapy in ovarian cancers expressing low Caspase 8 in vitro and in vivo**  
Lidia Hernandez, MS • National Cancer Institute

### BREAK

### ABSTRACT SESSION CONTINUED

**Feasibility of monitoring response to the PARP inhibitor rucaparib with targeted deep sequencing of circulating tumor DNA (ctDNA) in women with high grade ovarian carcinoma on the ARIEL2 trial**  
Anna Piskorz, PhD • CRUK Cambridge Institute University of Cambridge (United Kingdom)

**BRCA1 and RAD51C Promoter Hypermethylation Confer Sensitivity to PARP Inhibitors in Patients with Platinum Sensitive Ovarian Carcinoma**  
Elizabeth Swisher, MD • University of Washington

**BRCA1 RING Domain-Deficient Proteins Promote PARP Inhibitor and Platinum Resistance**  
Neil Johnson, PhD • Fox Chase Cancer Center

**Phase Ib/II with expansion of patients at the MTD study of olaparib plus weekly (metronomic) carboplatin and paclitaxel in relapsed ovarian cancer patients**  
Saul E. Rivkin, MD • Rivkin Center for Ovarian Cancer and Swedish Medical Center

**Targeting PD-L1/PD1 Pathway Through BET Protein Inhibition In Epithelial Ovarian Cancer**  
Hengrui Zhu, PhD • The Wistar Institute

**The methyltransferase EZH2 is a vulnerable target in small cell carcinoma of the ovary, hypercalcemic type (SCCOHT)**  
Yemin Wang, PhD • University of British Columbia (Canada)

### WRAP UP

Except where otherwise noted, all oral presentation sessions will be in Kane Hall.